Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 21266827)

1.

Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.

Koo JS, Jung W.

Pathobiology. 2010;77(6):289-300. doi: 10.1159/000320936. Epub 2011 Jan 24.

PMID:
21266827
2.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Zardavas D, Fumagalli D, Loi S.

Curr Opin Oncol. 2012 Nov;24(6):623-34. doi: 10.1097/CCO.0b013e328358a2b5. Review.

PMID:
22960556
3.

mTOR inhibitors in advanced breast cancer: ready for prime time?

Martin LA, André F, Campone M, Bachelot T, Jerusalem G.

Cancer Treat Rev. 2013 Nov;39(7):742-52. doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1. Review.

PMID:
23557794
4.

Emerging targeted therapies in triple-negative breast cancer.

Crown J, O'Shaughnessy J, Gullo G.

Ann Oncol. 2012 Aug;23 Suppl 6:vi56-65. Review.

5.

Targeting triple-negative breast cancer: optimising therapeutic outcomes.

Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S.

Ann Oncol. 2012 Sep;23(9):2223-34. doi: 10.1093/annonc/mds067. Epub 2012 Apr 19. Review.

6.

Current approaches to the management of Her2-negative metastatic breast cancer.

Gogineni K, DeMichele A.

Breast Cancer Res. 2012 Apr 10;14(2):205. Review.

7.

Triple-negative breast cancer: making the most of a misnomer.

McCarthy N, Mitchell G, Bilous M, Wilcken N, Lindeman GJ.

Asia Pac J Clin Oncol. 2012 Jun;8(2):145-55. doi: 10.1111/j.1743-7563.2012.01533.x. Review.

PMID:
22524573
8.

STAT signaling in different breast cancer sub-types.

Furth PA.

Mol Cell Endocrinol. 2014 Jan 25;382(1):612-5. doi: 10.1016/j.mce.2013.03.023. Epub 2013 Apr 3. Review.

9.

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

Villarreal-Garza C, Cortes J, Andre F, Verma S.

Ann Oncol. 2012 Oct;23(10):2526-35. Epub 2012 May 2. Review.

10.

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Fu X, Osborne CK, Schiff R.

Breast. 2013 Aug;22 Suppl 2:S12-8. doi: 10.1016/j.breast.2013.08.001. Epub 2013 Sep 5. Review.

11.

Growth control under stress: mTOR regulation through the REDD1-TSC pathway.

Ellisen LW.

Cell Cycle. 2005 Nov;4(11):1500-02. Epub 2005 Nov 1. Review.

12.

Hypoxia-inducible factor 1α in breast cancer prognosis.

Wang W, He YF, Sun QK, Wang Y, Han XH, Peng DF, Yao YW, Ji CS, Hu B.

Clin Chim Acta. 2014 Jan 20;428:32-7. Review.

PMID:
24482805
13.

Triple-negative breast carcinoma: current and emerging concepts.

Schmadeka R, Harmon BE, Singh M.

Am J Clin Pathol. 2014 Apr;141(4):462-77. doi: 10.1309/AJCPQN8GZ8SILKGN. Review.

14.

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions.

Witkiewicz AK, Knudsen ES.

Breast Cancer Res. 2014 May 7;16(3):207. doi: 10.1186/bcr3652. Review.

15.

Environmental and metabolic sensors that control T cell biology.

Ramsay G, Cantrell D.

Front Immunol. 2015 Mar 17;6:99. doi: 10.3389/fimmu.2015.00099. eCollection 2015. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk